Related Experiment Video
Updated: Jul 29, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
JAK-STAT pathway inhibitors in dermatology
Hélio Amante Miot1, Paulo Ricardo Criado2, Caio César Silva de Castro3
1Department of Dermatology, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil.
Anais Brasileiros De Dermatologia
|May 25, 2023
Summary
Janus kinase-STAT (JAK-STAT) pathway inhibitors are crucial for treating inflammatory skin conditions like psoriasis and atopic dermatitis. This review details their efficacy, safety, and immunological effects for optimal dermatological practice.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- The JAK-STAT signaling pathway regulates critical cellular functions including immune responses and cell differentiation.
- Dysregulation of this pathway is implicated in various diseases, including dermatological conditions.
- JAK-STAT pathway inhibitors offer therapeutic potential for a range of medical conditions.
Purpose of the Study:
- To review available Janus kinase-STAT (JAK-STAT) pathway inhibitors for dermatological applications.
- To discuss their immunological effects, pharmacological characteristics, clinical efficacy, and safety profiles.
- To guide best practices in dermatological prescriptions of these agents.
Main Methods:
- Literature review of JAK-STAT pathway inhibitors in dermatology.
- Analysis of immunological effects and pharmacological properties.
- Evaluation of clinical efficacy and safety data from relevant studies.
Main Results:
- JAK-STAT inhibitors are primarily used for inflammatory and autoimmune skin diseases like psoriasis, vitiligo, atopic dermatitis, and alopecia areata.
- Ongoing research is exploring their utility in additional dermatoses.
- The review synthesizes information on drug profiles, efficacy, and safety.
Conclusions:
- JAK-STAT pathway inhibitors are becoming increasingly important in dermatology.
- Understanding their mechanisms, efficacy, and safety is essential for clinical decision-making.
- This review provides a comprehensive resource for optimizing their use in treating skin diseases.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:25cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
200
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
200
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
717
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
717
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
01:16TGF - β Signaling Pathway
7.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K